Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | QPCT | Q16769 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8443962 | 0.99 | LMNA (0.56) | LMNAQPCTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8444094 | 0.95 | TP53 (0.52) | LMNAQPCTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8445868 | 0.94 | ALDH1A1 (0.51) | LMNAQPCTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8446124 | 0.94 | ALDH1A1 (0.51) | LMNAQPCTCYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL8949432 | 0.88 | ALDH1A1 (0.55) | LMNAQPCTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL8949449 | 0.87 | ALDH1A1 (0.56) | LMNAQPCTSMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL7879569 | 0.86 | QPCT (0.49) | LMNAQPCTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13696720 | 0.85 | CYP11B1 (0.55) | QPCTSMN1; SMN2ALDH1A1 | |
| Citric Acid SCHEMBL8445980 | 0.85 | LMNA (0.54) | LMNAQPCTCYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL8445789 | 0.85 | QPCT (0.51) | LMNAQPCTCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1892239-B1 | Inhibitors of cytosolic phospholipase A2 | WYETH LLC (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8283373-B2 | Inhibitors of cytosolic phospholipase A2 | PFIZER INC. (US) | 2012-10-09 | — | — | US | disclosed |
| CN-102040550-B | Inhibitors of cytosolic phospholipase A2 | WYETH CORP | 2012-10-03 | — | — | CN | disclosed |
| CN-101628888-B | Inhibitors of cytosolic phospholipase a2 | WYETH CORP | 2012-05-23 | — | — | CN | disclosed |
| CN-102040550-A | Inhibitors of cytosolic phospholipase A2 | WYETH CORP | 2011-05-04 | — | — | CN | disclosed |
| CN-101184729-B | Cytosolic phospholipase A2Inhibitors | WYETH CORP | 2011-02-16 | — | — | CN | disclosed |
| EP-2248801-A1 | Inhibitors of cytosolic phospholipase a2 | Wyeth LLC (US) | 2010-11-10 | — | — | EP | disclosed |
| US-7713964-B2 | Methods for treating asthmatic conditions | WYETH LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100029645-A1 | Inhibitors of Cytosolic Phospholipase A2 | WYETH LLC | 2010-02-04 | — | — | US | disclosed |
| US-20100022536-A1 | Inhibitors of Cytosolic Phospholipase A2 | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| EP-1451154-B1 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006128142-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
| CN-1617855-A | Cytosolic phospholipase A2Inhibitors | WYETH CORP (US) | 2005-05-18 | — | — | CN | disclosed |
| EP-1451154-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030149029-A1 | Methods for treating asthmatic conditions | WYETH | 2003-08-07 | — | — | US | disclosed |
| WO-2003048122-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-0618907-B1 | 1-(ARYLALKYL-AMINOALKYL)IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARATION AND USE AS THERAPEUTICAL AGENTS | BRITISH TECH GROUP INT (GB) | 1999-04-28 | — | — | EP | disclosed |
| US-5547972-A | 1-(ARLALKYLAMINOALKYL) IMIDAZOLE DERIVATIVES | THE BOOTS COMPANY PLC (GB) | 1996-08-20 | — | — | US | disclosed |
| WO-1993013075-A1 | 1-(ARYLALKYL-AMINOALKYL)IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARATION AND USE AS THERAPEUTICAL AGENTS | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022536-A1 | Inhibitors of Cytosolic Phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | LMNA 782/4885QPCT 1248/4885CYP1A2 722/4885 |
| US-20100029645-A1 | Inhibitors of Cytosolic Phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | LMNA 782/4885QPCT 1248/4885CYP1A2 722/4885 |
| US-20030149029-A1 | Methods for treating asthmatic conditions | PLA2G4A, PLA2G4B, PLA2G1B | LMNA 2545/4885QPCT 1341/4885CYP1A2 382/4885 |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | LMNA 782/4885QPCT 1248/4885CYP1A2 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.